Inhibikase Therapeutics, Inc.IKT
Key ratios
FCF / Sales
-6947.0%2023
ROA
-32.8%TTM
2025
-20.5%2024
-31.6%2023
-63.7%
ROE
-52.0%TTM
2025
-36.1%2024
-52.0%2023
-118.9%
Revenue growth
-100.0%TTM
2023
111.0%
Recent news
Inhibikase Therapeutics Announces Participation in Upcoming Investor Conferences During November 2026
Inhibikase Therapeutics Appoints Scott Wasserman to Board of Directors
Inhibikase Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Inhibikase Therapeutics Announces Second Quarter 2026 Financial Results and Highlights Recent Activity
Track IKT in your journal
Save it to a watchlist, run a reverse DCF, and keep your notes on the company in one place. Free to start.
Figures are sourced from third parties and shown for research only. They may be delayed or incomplete, and nothing on this page is investment advice or a recommendation to buy or sell. Read the full disclaimer